Alexander Edward Perl, MD, MS – Associate Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania
Alexander Edward Per, MD, MS emphasizes the need to unravel the intricacies of both primary and secondary resistance mechanisms associated with FLT3 inhibitors, highlighting their role in AML management. Discussions revolve around the potential of these inhibitors to target FLT3 mutations, while also addressing challenges such as polyclonality and the selection of resistant clones. The importance of achieving optimal disease response is underscored, with an emphasis on utilizing minimal residual disease (MRD) testing to guide treatment decisions and enhance patient outcomes.
He explores the effects of combining gilteritinib with other therapies, such as venetoclax, to augment treatment responses. Notably, the role of MRD testing emerges as a critical factor in predicting relapse and survival rates, providing a foundation for tailored treatment approaches.